Perspective Therapeutics (CATX) to Release Earnings on Wednesday

Perspective Therapeutics (NYSEAMERICAN:CATX) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to post earnings of ($0.36) per share and revenue of $0.2320 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 16, 2026 at 4:00 PM ET.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The company had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. On average, analysts expect Perspective Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Perspective Therapeutics Trading Down 5.2%

CATX stock opened at $4.95 on Wednesday. The business has a 50-day simple moving average of $4.26 and a 200 day simple moving average of $3.42. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16. The company has a quick ratio of 8.66, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd grew its holdings in shares of Perspective Therapeutics by 36.5% in the fourth quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock valued at $227,000 after acquiring an additional 22,074 shares in the last quarter. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the fourth quarter worth $31,000. Opaleye Management Inc. purchased a new position in Perspective Therapeutics in the fourth quarter worth $3,257,000. Engineers Gate Manager LP purchased a new position in Perspective Therapeutics in the fourth quarter worth $35,000. Finally, ADAR1 Capital Management LLC bought a new position in Perspective Therapeutics in the 4th quarter valued at $262,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. B. Riley Financial reduced their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a report on Tuesday. BTIG Research reiterated a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a research report on Tuesday. UBS Group reissued a “buy” rating and issued a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. Finally, Royal Bank Of Canada lowered their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.13.

Key Headlines Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated clinical data for the company’s lead radiopharmaceutical, [212Pb]VMT‑α‑NET, was accepted for a poster at the AACR Annual Meeting (April 20). The program’s interim safety and preliminary efficacy signals — no dose‑limiting toxicities reported and 76% of patients in the reported cohort without progression — increase visibility and could support future upside if further data confirm efficacy. Read More.
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and a $14 price target, signaling continued institutional confidence from at least one research shop — a supportive note for momentum traders and long-term holders. Read More.
• Positive Sentiment: Recent insider purchases (reported in Quiver) show company insiders adding shares, which can be interpreted as management confidence in the business and pipeline. Read More.
• Neutral Sentiment: RBC cut its price target from $18 to $14 but maintained an “Outperform” rating — a mixed signal (lower upside expectation but continued analyst support). This may temper upside while keeping institutional interest. Read More.
• Negative Sentiment: Recent financial results and the latest quarterly report show continuing operating losses (reported EPS of -$0.51 for the quarter and minimal revenue), a very negative net margin, and elevated cash‑burn risk — factors that increase financing and execution risk until positive clinical proof or clearer commercialization path emerges. Read More.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.